These proteins usually lack a clearly defined binding bag or enzyme domain, preventing the participation of stable inhibitors, thus limiting the development of treatment [1,2,3]
Interestingly, recent evidences indicate that GLP1R agonists can significantly reduce adverse cardiovascular events, renal dysfunction, and the incidence of stroke in the patients with diabetes 9,10,11,12
Para resolver esse desafio, a estratgia adotada foi manter a estrutura peptdica semelhante a liraglutida e ao GLP-1 endgeno, com uma modificao apenas na posio 8, substituindo Ala por Aib, conhecido por resistir clivagem pelo DPP-IV e ter alta afinidade pelo GLP-1R
Weight change typically becomes clearer over several weeks to months and depends on dose, diet, activity, sleep, and adherence